Status: Recruiting
Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
This study is to investigate the safety and tolerability of C402-CD19-CAR treatment in subjects with relapsed or refractory large B-cell lymphoma and further determine the recommended Phase 2 dose of C402-CD19-CAR.
Participants needed: 18
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Exuma Biotechnology Ltd.Updated: Jun 13, 2025Locations: 1
Eligibility criteria
Male or female 18-75 years (inclusive); [+15]
History of receiving allogeneic hematopoietic stem cell transplantation, adoptiv... [+14]